Mutant ASXL1 exacerbates CALR-mutant myeloproliferative neoplasms by enhancing a distinct megakaryocyte differentiation program
Journal of Clinical Investigation · 29.10.2026
DOI: 10.1172/jci201732 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 29.10.2026. Verfasst von Frederike Kramer und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH NHLBI; NIH Director’s Early Independence Award.
Abstract (Originalsprache)
ASXL1 mutations confer a poor prognosis in myeloid neoplasms, including in CALR-mutated myeloproliferative neoplasms (MPN). We generated Calr-Asxl1 co-mutant mice and found more severe thrombocytosis and increased splenomegaly, compared with Calr single-mutant animals. Calr-Asxl 1 co-mutant megakaryocytes displayed more pronounced morphological abnormalities and enhanced emperipolesis characteristic of inflammation. Concordant with this, a differentiation trajectory directly to megakaryocytes from hematopoietic stem cells (HSC) was more prominent in Calr-Asxl1 co-mutant mice. In this non-canonical trajectory, where megakaryocyte-biased HSCs directly differentiate into megakaryocyte progenitors, we found upregulation of Mef2c , a key transcriptional regulator of megakaryocyte lineage commitment. Mature Calr-Asxl1 co-mutant megakaryocytes displayed an enhanced proinflammatory transcriptional state, whereas the transcriptional signature of Calr-Asxl1 co-mutant HSCs was indicative of inflammation-resistance. Genotyping of transcriptomes (GoT) confirmed an activated megakaryocytic differentiation program in CALR-ASXL 1 co-mutant HSCs in primary human MPN bone marrow. These findings link the enhanced severity of CALR-ASXL1 co-mutant MPN to altered megakaryocyte differentiation and help explain some of the biological basis for the more severe MPN phenotype observed in patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America.
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, United States of America.
- Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, United States of America.
- The Broad Institute of MIT and Harvard, Cambridge, United States of America.
- Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America.
- Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, United States of America.
Förderung
- NHLBI NIH HHS
- NIH NHLBI; NIH Director’s Early Independence Award
Zitieren
APA
Kramer, F., Riedemann, M., Abera, T. A., Hem, J., Herce, A., Marneth, A. E., Rolles, B., Englert, M., Hackenbroch, C., Faiz, M., Papanastasiou, M., Reiter, A. H., Carr, S. A., Li, R., Qiu, X., Hobbs, G. S., Fouda, R., Pozdnyakova, O., Miyauchi, M., …, & Mullally, A. (2026). Mutant ASXL1 exacerbates CALR-mutant myeloproliferative neoplasms by enhancing a distinct megakaryocyte differentiation program. Journal of Clinical Investigation. https://doi.org/10.1172/jci201732
Vancouver
Kramer F, Riedemann M, Abera TA, Hem J, Herce A, Marneth AE, et al. Mutant ASXL1 exacerbates CALR-mutant myeloproliferative neoplasms by enhancing a distinct megakaryocyte differentiation program. Journal of Clinical Investigation. 2026. doi:10.1172/jci201732
BibTeX
@article{Kramer2026,
author = {Kramer, Frederike and Riedemann, Merle and Abera, Tsega-Ab and Hem, Jessica and Herce, Adela and Marneth, Anna E and Rolles, Benjamin and Englert, Maximilian and Hackenbroch, Christian and Faiz, Mifra and Papanastasiou, Malvina and Reiter, Andrew H and Carr, Steven A and Li, Rong and Qiu, Xintao and Hobbs, Gabriela S and Fouda, Raghda and Pozdnyakova, Olga and Miyauchi, Masashi and Nam, Anna S and Mullally, Ann},
title = {Mutant ASXL1 exacerbates CALR-mutant myeloproliferative neoplasms by enhancing a distinct megakaryocyte differentiation program},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci201732}
}
EUVIMED